In patients with GGG ≥ 3, we might further substage pT2 according to tumor burden to guide subsequent more precise follow-up and treatments strategies, such as performing prostate-specific membrane antigen (PSMA) -PET/CT or salvage lymph node dissection (12, 13). The gene discussed is FOLH1; the disease is neoplasm.